Pain Therapeutics (NASDAQ:PTIE) saw strong trading volume on Monday . 403,089 shares changed hands during mid-day trading, an increase of 82% from the previous session’s volume of 221,465 shares.The stock last traded at $2.51 and had previously closed at $2.54.

A number of equities research analysts recently issued reports on the stock. Gabelli lowered shares of Pain Therapeutics from a “buy” rating to a “hold” rating and set a $2.50 price objective for the company. in a report on Tuesday, September 13th. Zacks Investment Research raised shares of Pain Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Saturday.

The stock’s 50 day moving average price is $2.49 and its 200 day moving average price is $2.31. The stock’s market capitalization is $114.89 million.

Pain Therapeutics (NASDAQ:PTIE) last released its earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. On average, equities research analysts expect that Pain Therapeutics will post ($0.46) EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in PTIE. Gagnon Securities LLC increased its stake in Pain Therapeutics by 11.5% in the first quarter. Gagnon Securities LLC now owns 69,996 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 7,197 shares during the period. Brandes Investment Partners LP increased its stake in Pain Therapeutics by 108.8% in the second quarter. Brandes Investment Partners LP now owns 78,758 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 41,039 shares during the period. Acadian Asset Management LLC increased its stake in Pain Therapeutics by 0.7% in the second quarter. Acadian Asset Management LLC now owns 351,072 shares of the biopharmaceutical company’s stock worth $769,000 after buying an additional 2,471 shares during the period. Bridgeway Capital Management Inc. increased its stake in Pain Therapeutics by 29.8% in the second quarter. Bridgeway Capital Management Inc. now owns 435,853 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 100,000 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Pain Therapeutics by 8.1% in the first quarter. Renaissance Technologies LLC now owns 726,987 shares of the biopharmaceutical company’s stock worth $1,621,000 after buying an additional 54,200 shares during the period. 55.07% of the stock is owned by institutional investors.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

5 Day Chart for NASDAQ:PTIE

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.